Bill Summary
The "Responsibility in Drug Advertising Act of 2025" seeks to amend the Federal Food, Drug, and Cosmetic Act to impose restrictions on direct-to-consumer advertising of prescription drugs. Under this legislation, pharmaceutical companies are prohibited from advertising newly approved drugs directly to consumers for the first three years following the drug's approval by the FDA.
There is a provision allowing the Secretary of Health and Human Services to grant a waiver during the third year if the company can demonstrate that advertising the drug would positively impact public health. After the initial three-year period, the Secretary retains the authority to prohibit advertising if there are significant adverse health effects associated with the drug, based on various assessments and studies.
Additionally, the legislation mandates the Secretary to revise existing regulations related to drug advertisements within one year of enactment to align with these new restrictions. Overall, the Act aims to ensure that drug advertising is responsible and considers the potential health impacts of newly approved medications.
Possible Impacts
The "Responsibility in Drug Advertising Act of 2025" could affect people in several ways:
1. **Reduced Exposure to Potentially Misleading Information**: With the restriction on direct-to-consumer advertising for newly approved drugs during the first three years, individuals may be less susceptible to misleading claims about the efficacy and safety of these drugs. This could help prevent patients from seeking medications based on advertisements that may not fully disclose potential side effects or risks associated with the drug.
2. **Informed Healthcare Decisions**: By delaying direct-to-consumer advertising, the legislation allows more time for post-approval studies and monitoring of new drugs' safety and efficacy to be conducted. This could lead to more informed healthcare decisions, as patients and providers can rely on more comprehensive data rather than promotional material. Patients may have better discussions with their healthcare providers based on solid evidence rather than advertisements.
3. **Public Health Implications**: The provision allowing the Secretary of Health and Human Services to waive advertising restrictions if deemed beneficial for public health may lead to better-targeted information dissemination when necessary. For example, if a new drug addresses a significant public health crisis, early advertising could help ensure that affected populations receive timely access to potentially life-saving treatments. However, this could also raise concerns about the quality and thoroughness of the information provided if not closely monitored.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 483 Introduced in Senate (IS)]
<DOC>
119th CONGRESS
1st Session
S. 483
To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-
to-consumer drug advertising.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
February 6 (legislative day, February 5), 2025
Mr. King (for himself, Mr. Kaine, and Mr. Welch) introduced the
following bill; which was read twice and referred to the Committee on
Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-
to-consumer drug advertising.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Responsibility in Drug Advertising
Act of 2025''.
SEC. 2. DIRECT-TO-CONSUMER DRUG ADVERTISING.
The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is
amended--
(1) in section 301 (21 U.S.C. 331), by adding at the end
the following:
``(jjj) The conduct of direct-to-consumer advertising of a drug in
violation of section 506M.''; and
(2) in chapter V, by inserting after section 506L (21
U.S.C. 356l) the following:
``SEC. 506M. DIRECT-TO-CONSUMER DRUG ADVERTISING.
``(a) Prohibitions.--
``(1) First 3 years.--
``(A) In general.--Subject to subparagraph (B), no
person shall conduct direct-to-consumer advertising,
including on a social media platform, of a drug
approved under section 505(c) before the end of the 3-
year period beginning on the date of such approval.
``(B) Waiver.--The Secretary may waive the
application of subparagraph (A) to a drug during the
third year of the 3-year period described in such
subparagraph if--
``(i) the sponsor of the drug submits an
application to the Secretary pursuant to
subparagraph (C); and
``(ii) the Secretary, after considering the
application and any accompanying materials,
determines that direct-to-consumer advertising
of the drug would have an affirmative value to
public health.
``(C) Application for waiver.--To seek a waiver
under subparagraph (B), the sponsor of a drug shall
submit an application to the Secretary at such time, in
such manner, and containing such information as the
Secretary may require.
``(2) Subsequent years.--The Secretary may prohibit direct-
to-consumer advertising, including on social media platforms,
of a drug during the period beginning at the end of the 3-year
period described in paragraph (1)(A) if the Secretary
determines that the drug has significant adverse health effects
based on post-approval studies, risk-benefit analyses, adverse
event reports, the scientific literature, any clinical or
observational studies, or any other appropriate resource.
``(b) Regulations.--Not later than 1 year after the date of the
enactment of this section, the Secretary shall revise the regulations
promulgated under this Act governing drug advertisements to the extent
necessary to implement this section.
``(c) Rule of Construction.--This section shall not be construed to
diminish the authority of the Secretary to prohibit or regulate direct-
to-consumer advertising of drugs, including on social media platforms,
under any other provision of law.
``(d) Effective Date.--This section applies only with respect to a
drug approved under section 505(c) on or after the date that is 1 year
before the date of enactment of this section.''.
<all>